Corcept Therapeutics Incorporated
DE ˙ DB ˙ US2183521028
63,98 € ↑2,18 (3,53%)
2026-06-04
AKTIENPREIS
SecurityDE:HTD / Corcept Therapeutics Incorporated
InstitutionRoyce & Associates Lp
ManagerChuck Royce
Latest Disclosed Ownership135,430 shares
Latest Disclosed Value $ 5,459,183
Royce & Associates Lp reports 18.69% decrease in ownership of HTD / Corcept Therapeutics Incorporated

On May 12, 2026 - Royce & Associates Lp filed a 13F-HR form disclosing ownership of 135,430 shares of Corcept Therapeutics Incorporated (DE:HTD) valued at $4,670,981 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 9, 2026 disclosing 166,562 shares of Corcept Therapeutics Incorporated. This represents a change in shares of -18.69% during the quarter. The current value of the position is $8,664,811 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-12 2026-03-31 13F CORCEPT THERAPEUTICS COM 218352102 135,430 -31,132 -18.69 5,459 -5.81 0.0539
2026-02-09 2025-12-31 13F CORCEPT THERAPEUTICS COM 218352102 166,562 -1,997 -1.18 5,796 -58.62 0.0588
2025-11-12 2025-09-30 13F CORCEPT THERAPEUTICS COM 218352102 168,559 0 0.00 14,009 13.22 0.1397
2025-08-11 2025-06-30 13F CORCEPT THERAPEUTICS COM 218352102 168,559 -20,755 -10.96 12,372 -42.78 0.1270
2025-05-06 2025-03-31 13F CORCEPT THERAPEUTICS COM 218352102 189,314 -148,986 -44.04 21,623 26.85 0.2344
2025-02-10 2024-12-31 13F CORCEPT THERAPEUTICS COM 218352102 338,300 -24,972 -6.87 17,047 1.39 0.1582
2024-11-06 2024-09-30 13F CORCEPT THERAPEUTICS COM 218352102 363,272 13,000 3.71 16,812 47.73 0.1528
2024-08-13 2024-06-30 13F CORCEPT THERAPEUTICS COM 218352102 350,272 14,000 4.16 11,380 34.36 0.1064
2024-05-13 2024-03-31 13F CORCEPT THERAPEUTICS COM 218352102 336,272 197 0.06 8,471 -22.40 0.0756
2024-02-12 2023-12-31 13F CORCEPT THERAPEUTICS COM 218352102 336,075 -17,029 -4.82 10,916 13.46 0.1008
2023-11-09 2023-09-30 13F CORCEPT THERAPEUTICS COM 218352102 353,104 59,363 20.21 9,620 47.21 0.0980
2023-08-07 2023-06-30 13F CORCEPT THERAPEUTICS COM 218352102 293,741 -12,513 -4.09 6,536 -1.48 0.0635
2023-05-23 2023-03-31 13F/A-1 CORCEPT THERAPEUTICS COM 218352102 306,254 46,780 18.03 6,633 25.89 0.0664
2023-05-04 2023-03-31 13F CORCEPT THERAPEUTICS COM 218352102 306,254 46,780 7 0.0664
2023-05-23 2022-12-31 13F/A-1 CORCEPT THERAPEUTICS COM 218352102 259,474 -13,239 -4.85 5,270 -24.64 0.0554
2023-02-13 2022-12-31 13F CORCEPT THERAPEUTICS COM 218352102 259,474 -13,239 5 0.0551
2022-11-03 2022-09-30 13F CORCEPT THERAPEUTICS COM 218352102 272,713 -7,737 -2.76 6,992 4.84 0.0791
2022-08-04 2022-06-30 13F CORCEPT THERAPEUTICS COM 218352102 280,450 69 0.02 6,669 5.62 0.0687
2022-05-05 2022-03-31 13F CORCEPT THERAPEUTICS COM 218352102 280,381 227,477 429.98 6,314 503.06 0.0536
2022-02-07 2021-12-31 13F CORCEPT THERAPEUTICS COM 218352102 52,904 3,041 6.10 1,047 6.73 0.0078
2021-11-10 2021-09-30 13F CORCEPT THERAPEUTICS COM 218352102 49,863 -2,310 -4.43 981 -14.55 0.0073
2021-08-06 2021-06-30 13F CORCEPT THERAPEUTICS COM 218352102 52,173 -270 -0.51 1,148 -8.01 0.0079
2021-05-10 2021-03-31 13F CORCEPT THERAPEUTICS COM 218352102 52,443 -8,760 -14.31 1,248 -22.05 0.0084
2021-02-08 2020-12-31 13F CORCEPT THERAPEUTICS COM 218352102 61,203 -1,503 -2.40 1,601 46.75 0.0132
2020-11-12 2020-09-30 13F CORCEPT THERAPEUTICS COM 218352102 62,706 -570 -0.90 1,091 2.54 0.0118
2020-08-07 2020-06-30 13F CORCEPT THERAPEUTICS COM 218352102 63,276 -2,165 -3.31 1,064 36.76 0.0117
2020-05-12 2020-03-31 13F CORCEPT THERAPEUTICS COM 218352102 65,441 -1,271 -1.91 778 -3.59 0.0106
2020-02-06 2019-12-31 13F CORCEPT THERAPEUTICS COM 218352102 66,712 6,915 11.56 807 -4.50 0.0072
2019-11-13 2019-09-30 13F CORCEPT THERAPEUTICS COM 218352102 59,797 20,298 51.39 845 92.05 0.0078
2019-08-12 2019-06-30 13F CORCEPT THERAPEUTICS COM 218352102 39,499 17,093 76.29 440 67.30 0.0040
2019-05-09 2019-03-31 13F CORCEPT THERAPEUTICS COM 218352102 22,406 21,159 1,696.79 263 1,447.06 0.0022
2019-02-11 2018-12-31 13F CORCEPT THERAPEUTICS COM 218352102 1,247 -371 -22.93 17 -26.09 0.0002
2018-11-13 2018-09-30 13F CORCEPT THERAPEUTICS COM 218352102 1,618 871 116.60 23 91.67 0.0002
2018-08-09 2018-06-30 13F CORCEPT THERAPEUTICS COM 218352102 747 747 12 0.0001
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.